MK-0731

CAT: 0804-HY-50672-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-50672-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy[1][2].
CAS Number
[845256-65-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Kinesin; Lipoxygenase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mk-0731.html
Purity
99.85
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N(C)[C@@H](CC1)[C@H](F)CN1C)N2[C@@](C3=CC=CC=C3)(CO)C=C(C4=CC(F)=CC=C4F)C2
Molecular Formula
C25H28F3N3O2
Molecular Weight
459.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Christopher D Cox, et al. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S) -4- (2,5-difluorophenyl) -n-[ (3R,4S) -3-fluoro-1-methylpiperidin-4-yl]-2- (hydroxymethyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem. 2008 Jul 24;51 (14) :4239-52.|[2]Kyle Holen, et al. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Jun;30 (3) :1088-95.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Kinesin-5/Eg5/KSP

Popular Products